• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S ADR (NY: NVO )

    111.94 -0.01 (-0.01%)
    Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Novo Nordisk A/S ADR

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    60 61 Next >
    Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
    Via Investor's Business Daily
    Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
    Novo Nordisk's ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. 
    Via Benzinga
    Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
    Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. 
    Via Benzinga
    Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
    Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors 
    Via MarketBeat
    Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
    Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's... 
    Via Benzinga
    Exposures Product Safety
    How Is The Market Feeling About Novo Nordisk?
    Via Benzinga
    Market Whales and Their Recent Bets on NVO Options
    Via Benzinga
    Smitten With Novo Nordisk
    Sorry to go on and on about Novo Nordisk, but this bearish position is by far my favorite right now. 
    Via Talk Markets
    Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
    The company expects to have topline results from a Phase 2 study later this year. 
    Via Investor's Business Daily
    AMD Earnings Show Power Of Nvidia Software, ADP Data Defies Expectations
    To gain an edge, this is what you need to know today. 
    Via Benzinga
    A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
    Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth. 
    Via The Motley Fool
    1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
    One key disease-prevention market is drawing closer to being within reach. 
    Via The Motley Fool
    Behind the Scenes of Novo Nordisk's Latest Options Trends
    Via Benzinga
    Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
    Via Benzinga
    Neuralink's Promise For Alzheimer's Has A Crucial Time Window — Elon Musk Explains Why
    Elon Musk hinted that Neuralink may develop a brain implant to treat early-stage Alzheimer's, although he noted its limited effectiveness for advanced cases due to extensive neuronal loss. 
    Via Benzinga
    This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
    Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus. 
    Via The Motley Fool
    Benzinga Bulls And Bears: Nvidia, Tesla, MicroStrategy, Plug Power — And Crypto Traders Anticipate Dogecoin Topping 50 Cents
    Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. 
    Via Benzinga
    Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows
    Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA considers banning compounded versions. 
    Via Benzinga
    Exposures Product Safety
    Hims & Hers Stock Dropped: Here's What You Need to Know
    The GLP-1 drama continues at Hims & Hers. 
    Via The Motley Fool
    Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
    Via Benzinga
    Exposures Product Safety
    Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
    Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
    Via Benzinga
    Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
    Novo Nordisk just hit a technical red flag with a Death Cross, but its strong fundamentals suggest a potential rebound. 
    Via Benzinga
    Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
    Don't overlook NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO)—a stock with solid growth prospects and a reasonable valuation. 
    Via Chartmill
    Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
    Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. 
    Via Benzinga
    Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
    The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
    Via Investor's Business Daily
    Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
    Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type 2 diabetes. Regulatory filings for Rybelsus expansion expected by 2025. 
    Via Benzinga
    After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
    Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
    Via Benzinga
    Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
    Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in... 
    Via Benzinga
    Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
    A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients with OUD and AUD, offering potential new treatments for addiction. 
    Via Benzinga
    'Miracle' Weight Loss Drug Ozempic And Similar Drugs Reduce Alcohol And Opioid Overdose, Study Reveals
    Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing substance abuse. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    60 61 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.